ArticleFrontiers in neurology2019

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.

Paul Lingor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.